Genomics-Driven Precision Medicine for Advanced Pancreatic Cancer: Early Results from the COMPASS Trial
Open accessPublished version of a preprint
The DOI matches its Crossref record; 48 of the 48 references it cites were found in a registry or an index.
Abstract
Purpose: To perform real-time whole genome sequencing (WGS) and RNA sequencing (RNASeq) of advanced pancreatic ductal adenocarcinoma (PDAC) to identify predictive mutational and transcriptional features for better treatment selection. Experimental Design: Patients with advanced PDAC were prospectively recruited prior to first-line combination chemotherapy. Fresh tumor tissue was acquired by image-guided percutaneous core biopsy for WGS and RNASeq. Laser capture microdissection was performed for all cases. Primary endpoint was feasibility to report WGS results prior to first disease assessment CT scan at 8 weeks. The main secondary endpoint was discovery of patient subsets with predictive mutational and transcriptional signatures. Results: Sixty-three patients underwent a tumor biopsy between December 2015 and June 2017. WGS and RNASeq were successful in 62 (98%) and 60 (95%), respectively. Genomic results were reported at a median of 35 days (range, 19–52 days) from biopsy, meeting the primary feasibility endpoint. Objective responses to first-line chemotherapy were significantly better in patients with the classical PDAC RNA subtype compared with those with the basal-like subtype (P = 0.004). The best progression-free survival was observed in those with classical subtype treated with m-FOLFIRINOX. GATA6 expression in tumor measured by RNA in situ hybridization was found to be a robust surrogate biomarker for differentiating classical and basal-like PDAC subtypes. Potentially actionable genetic alterations were found in 30% of patients. Conclusions: Prospective genomic profiling of advanced PDAC is feasible, and our early data indicate that chemotherapy response differs among patients with different genomic/transcriptomic subtypes. Clin Cancer Res; 24(6); 1344–54. ©2017 AACR.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Patients with classical subtype of PDAC had superior responses to first line 5-flurouracil-basd regimens than those with “basal-like” cancers138”
From Pancreatic cancer: Advances and challenges (2023) · cites this paper as [138]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Encouragingly, early passages of PDAC PDOs maintain genomic and transcriptomic features of the tumor of origin, and harbor a gene signature of response to commonly used cytotoxic agents, enabling therapeutic prediction7,8.”
From Occult polyclonality of preclinical pancreatic cancer models drives in vitro evolution (2022) · cites this paper as [7]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“genetic alterations alone cannot explain this5”
From Microbiota-derived 3-IAA influences chemotherapy efficacy in pancreatic cancer (2023) · cites this paper as [6]
Experimental — accuracy not yet measuredThe cited source says what the claim attributes to it.
In the citing paper
“Patient data suggest that the classical subtype of PDAC responds better to chemotherapy than the poorly prognostic basal-like PDAC subtype (44, 58, 59).”
From Mechanisms of Resistance to Oncogenic KRAS Inhibition in Pancreatic Cancer (2024) · cites this paper as [58]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Subramanian, A., Tamayo, P., Mootha, V. K., Mukherjee, S., Ebert, B. L., Gillette, M. A., Paulovich, A., Pomeroy, S. L., Golub, T. R., Lander, E. S., et al. (2005) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0506580102 · Cited by 53,625
KEGG: Kyoto Encyclopedia of Genes and Genomes
Kanehisa, M. (2000) · Nucleic Acids Research · doi:10.1093/nar/28.1.27 · Cited by 37,077 · cited 1×
“1 (18, 20, 21) that includes the Kyoto encyclopedia of genes and genomes (KEGG) pathways (22) and Reactome pathways (23, 24).”
BackgroundKEGG: Kyoto Encyclopedia of Genes and Genomes
Ogata, H., Goto, S., Sato, K., Fujibuchi, W., Bono, H., & Kanehisa, M. (1999) · Nucleic Acids Research · doi:10.1093/nar/27.1.29 · Cited by 31,232
PD-1 and PD-L1 Immune Checkpoint Blockade to Treat Breast Cancer
Hartkopf, A. D., Taran, F.-A., Wallwiener, M., Walter, C. B., Krämer, B., Grischke, E.-M., & Brucker, S. Y. (2016) · Breast Care · doi:10.1159/000453569 · Cited by 30,845
The Molecular Signatures Database Hallmark Gene Set Collection
Liberzon, A., Birger, C., Thorvaldsdóttir, H., Ghandi, M., Mesirov, J. P., & Tamayo, P. (2015) · Cell Systems · doi:10.1016/j.cels.2015.12.004 · Cited by 13,807
Nishimura, R., Osako, T., Nishiyama, Y., Tashima, R., Nakano, M., Fujisue, M., Toyozumi, Y., & Arima, N. (2013) · Oncology · doi:10.1159/000353099 · Cited by 13,166
Comprehensive molecular portraits of human breast tumours
The Cancer Genome Atlas Network (2012) · Nature · doi:10.1038/nature11412 · Cited by 12,129
Mootha, V. K., Lindgren, C. M., Eriksson, K.-F., Subramanian, A., Sihag, S., Lehar, J., Puigserver, P., Carlsson, E., Ridderstråle, M., Laurila, E., et al. (2003) · Nature Genetics · doi:10.1038/ng1180 · Cited by 10,197
FOLFIRINOX versus Gemcitabine for Metastatic Pancreatic Cancer
Conroy, T., Desseigne, F., Ychou, M., Bouché, O., Guimbaud, R., Bécouarn, Y., Adenis, A., Raoul, J.-L., Gourgou-Bourgade, S., de la Fouchardière, C., et al. (2011) · New England Journal of Medicine · doi:10.1056/nejmoa1011923 · Cited by 7,810
Spencer, P. M., Cameron, J. L., & Lin, L. (2000) · Cited by 7,202
Research works printed but not linked: 1
- Hidalgo, 2015 5–9, Palbociclib potentiates nab-paclitaxel efficacy in pancreatic ductal adenocarcinoma. [abastract]
Cited by
Park, W., Chawla, A., & O’Reilly, E. M. (2021) · JAMA · doi:10.1001/jama.2021.13027 · Cited by 1,882
Pancreatic cancer: Advances and challenges
Halbrook, C. J., Lyssiotis, C. A., Pasca di Magliano, M., & Maitra, A. (2023) · Cell · doi:10.1016/j.cell.2023.02.014 · Cited by 1,321
Organoid Profiling Identifies Common Responders to Chemotherapy in Pancreatic Cancer
Tiriac, H., Belleau, P., Engle, D. D., Plenker, D., Deschênes, A., Somerville, T. D. D., Froeling, F. E. M., Burkhart, R. A., Denroche, R. E., Jang, G.-H., et al. (2018) · Cancer Discovery · doi:10.1158/2159-8290.cd-18-0349 · Cited by 1,092
“398 Finally, the chemo-sensitivity signatures were applied to an independent transcriptomic data set obtained 399 from tumors of PDAC patients on the COMPASS trial (26).”
BackgroundMethodSelf-citationMolecular subtypes of pancreatic cancer
Collisson, E. A., Bailey, P., Chang, D. K., & Biankin, A. V. (2019) · Nature Reviews Gastroenterology & Hepatology · doi:10.1038/s41575-019-0109-y · Cited by 892
Transcription phenotypes of pancreatic cancer are driven by genomic events during tumor evolution
Chan-Seng-Yue, M., Kim, J. C., Wilson, G. W., Ng, K., Figueroa, E. F., O’Kane, G. M., Connor, A. A., Denroche, R. E., Grant, R. C., McLeod, J., et al. (2020) · Nature Genetics · doi:10.1038/s41588-019-0566-9 · Cited by 669
Self-citation
Metadata
- Authors
- Aung, K. L., Fischer, S. E., Denroche, R. E., Jang, G.-H., Dodd, A., Creighton, S., Southwood, B., Liang, S.-B., Chadwick, D., Zhang, A., O'Kane, G. M., Albaba, H., Moura, S., Grant, R. C., Miller, J. K., Mbabaali, F., Pasternack, D., Lungu, I. M., Bartlett, J. M. S., Ghai, S., Lemire, M., Holter, S., Connor, A. A., Moffitt, R. A., Yeh, J. J., Timms, L., Krzyzanowski, P. M., Dhani, N., Hedley, D., Notta, F., Wilson, J. M., Moore, M. J., Gallinger, S., & Knox, J. J.
- Affiliations
- University Health Network (CA)
- Ontario Institute for Cancer Research (CA)
- Mount Sinai Hospital (CA)
- University of North Carolina at Chapel Hill (US)
- BC Cancer Agency (CA)
- 1Wallace McCain Centre for Pancreatic Cancer, Department of Medical Oncology, Princess Margaret Cancer Centre, University Health Network, University of Toronto, Toronto, Ontario, Canada.
- Corresponding author
- Knox, Jennifer J.
- ORCID
- Aung, Kyaw L.
- Fischer, Sandra E.
- Denroche, Robert E.
- Jang, Gun-Ho
- Dodd, Anna
- Liang, Sheng-Ben
- Zhang, Amy
- O'Kane, Grainne M.
- Moura, Shari
- Grant, Robert C.
- Miller, Jessica K.
- Lungu, Ilinca M.
- Bartlett, John M.S.
- Ghai, Sangeet
- Lemire, Mathieu
- Connor, Ashton A.
- Moffitt, Richard A.
- Yeh, Jen Jen
- Krzyzanowski, Paul M.
- Dhani, Neesha
- Hedley, David
- Notta, Faiyaz
- Wilson, Julie M.
- Moore, Malcolm J.
- Knox, Jennifer J.
- Venue
- Clinical Cancer Research
- Published
- 2018-03-14
- Volume
- 24
- Issue
- 6
- Pages
- 1344-1354
- ISSN
- 1078-0432 (ISSN-L)
- 1557-3265
- PMC
- PMC5968824
- OpenAlex
- W2780727948
- Cited by
- 618
- References
- 48
- Citations by year
- 2026: 48 · 2025: 75 · 2024: 73 · 2023: 85 · 2022: 76 · 2021: 117 · 2020: 71 · 2019: 52 · 2018: 17
- FWCI
- 16.99
- Type
- journal article
- Language
- en
- Open access
- green
- europepmc.org
- Locations
- Clinical Cancer Research (publishedVersion)
- PubMed (publishedVersion)
- Europe PMC (PubMed Central) (acceptedVersion)
- PubMed Central (acceptedVersion)
- Carolina Digital Repository (University of North Carolina at Chapel Hill) (submittedVersion)
- UNC Libraries
- Funders
- Ontario Institute for Cancer Research (OICR)
- Canadian Cancer Society Research Institute (CCSRI) (702316)
- Canadian Friends of Tel Aviv University (CFTAU)
- HHS | NIH | National Cancer Institute (NCI) (CA193650)
- Division of Cancer Prevention, National Cancer Institute (DCP, NCI) (CA199064)
- Topics
- Health Sciences › Medicine › Oncology › Pancreatic and Hepatic Oncology Research
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Cancer Research › Cancer Genomics and Diagnostics
- Health Sciences › Medicine › Surgery › Cholangiocarcinoma and Gallbladder Cancer Studies
- Keywords
- pancreatic ductal adenocarcinoma, precision oncology, whole genome sequencing, RNA sequencing, predictive biomarkers, classical subtype, basal-like subtype, first-line chemotherapy response, actionable genomic alterations, tumor biopsy, COMPASS trial
- MeSH terms
- Exome Sequencing, Adult, Aged, Clinical Trials as Topic, DNA Damage, Female, Humans, Male, Middle Aged, Mutation, Neoplasm Metastasis, Neoplasm Staging, Pancreatic Neoplasms, Biomarkers, Tumor, Disease Progression, Disease Management, Genomics, GATA6 Transcription Factor, Precision Medicine, Transcriptome
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Genomics-Driven Precision Medicine for Advanced Pancreatic Cancer: Early Results from the COMPASS Trial. https://app.cochat.ai/papers/10.1158/1078-0432.ccr-17-2994
- The paper
- Aung, K. L., Fischer, S. E., Denroche, R. E., Jang, G.-H., Dodd, A., Creighton, S., Southwood, B., Liang, S.-B., Chadwick, D., Zhang, A., O'Kane, G. M., Albaba, H., Moura, S., Grant, R. C., Miller, J. K., Mbabaali, F., Pasternack, D., Lungu, I. M., Bartlett, J. M. S., . . . Knox, J. J. (2018). Genomics-Driven Precision Medicine for Advanced Pancreatic Cancer: Early Results from the COMPASS Trial. Clinical Cancer Research. https://doi.org/10.1158/1078-0432.ccr-17-2994
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.